ENPP2 and hepatocellular carcinoma: In each case, the levels of the following markers were lower in the HBV patients with HCC: M2BPGi (HBV, HCV, NASH: and ASH; 1.5 ± 1.1, 4.0 ± 4.2, 3.2 ± 2.5, and 4.9 ± 3.7 cut‐off index [COI], respectively), ATX (1.1 ± 0.4, 1.4 ± 1.0, 1.6 ± 0.6, and 1.4 ± 0.5 mg/L, respectively), and FIB‐4 index (2.5 ± 1.5, 2.8 ± 0.7, 4.5 ± 3.5, and 4.9 ± 3.9, respectively), but the platelet count was almost the same in these patients (13.8 ± 4.0, 15.6 ± 4.5, 15.0 ± 4.8, 12.7 ± 8.0 × 104/μL, respectively), suggesting that HBV patients must be followed up regardless of the levels of these fibrosis markers.